Sale to Maravai LifeSciences in Partnership with GTCR
Baird served as exclusive financial advisor to Vector Laboratories, Inc.
AboutVector Laboratories, Inc. ("Vector") was recently acquired by GTCR, LLC (“GTCR”), through GTCR's previously established Maravai LifeSciences ("Maravai") management partnership with CEO Carl Hull.
Vector is a specialized life science tools company that provides researchers with labeling and detection reagents, which are critical components in immunohistochemistry studies and other life science research applications. Vector’s products are frequently cited in peer-reviewed academic journals and its customer base includes researchers at some of the world's leading hospitals, academic research institutions and life science companies. Vector was founded in 1976 and is headquartered in Burlingame, California.
Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries. GTCR pioneered The Leaders Strategy™—finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $12 billion in over 200 companies. GTCR is headquartered in Chicago, Illinois.
Maravai was formed in 2014 as a partnership between Carl Hull, Eric Tardif and GTCR. Maravai's mission is to build a transformative company in the life sciences tools and in vitro diagnostics markets by acquiring outstanding businesses in these spaces and accelerating their growth. Maravai is headquartered in San Diego, California.
For additional information about this transaction, please contact:
- May 2016
- Vector Laboratories, Inc.
- Target Location
- North America
- Acquiror Location
- North America